Long‐Term Oncologic Outcomes of Neoadjuvant Tumor‐Directed Immunotherapy (PROSTVAC) Before Radical Prostatectomy for Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Trial

医学 前列腺切除术 免疫疗法 肿瘤科 免疫系统 内科学 前列腺癌 新辅助治疗 泌尿科 前列腺 前列腺特异性抗原 CD8型 化疗 原发性肿瘤 生化复发 手术切缘 转移 根治性手术 激素疗法 局限性疾病 放射治疗 临床研究阶段 抗原
作者
Braden Millan,Alexander P. Kenigsberg,Charles Hesswani,Christopher R. Koller,Sahil H. Parikh,Zoë Blake,Hangcheng Fu,Ruben Blachman-Braun,Patrick Michael,Sandeep Gurram,Barış Türkbey,Howard L. Parnes,Fatima H. Karzai,Renee Nicole Donahue,Jeffrey Schlom,James L. Gulley,Peter A. Pinto
出处
期刊:The Prostate [Wiley]
卷期号:86 (15): 1518-1524
标识
DOI:10.1002/pros.70224
摘要

BACKGROUND: Biochemical recurrence (BCR) following radical prostatectomy (RP) occurs in 20%-40% of patients with localized prostate cancer. Neoadjuvant PROSTVAC has been shown to enhance T-cell infiltration into the tumor immune microenvironment, but whether these immunologic changes translate into improved long-term oncologic outcomes remains unknown. PATIENTS AND METHODS: This secondary analysis evaluated 26 patients from a Phase II neoadjuvant PROSTVAC trial who underwent RP. Patients received recombinant vaccinia-PSA-TRICOM priming followed by three fowlpox-PSA-TRICOM boosts before surgery. Tumor immune responses (CD4 + /CD8 + T-cell infiltration) and peripheral antigen-specific T-cell responses to PSA, MUC-1, and brachyury were previously assessed. Primary outcomes included BCR-free survival (BCR-FS) and metastatic progression at extended follow-up. RESULTS: From May 2014 to June 2017, 26 patients were enrolled, received neoadjuvant PROSTVAC, and subsequently underwent RP. Eighteen (69.2%) patients had NCCN® unfavorable-intermediate, high, or very high-risk disease at baseline. At a median follow-up of 8.9 years (range 7.0-10.1), BCR occurred in six patients (23.1%), and none developed metastatic disease. Comparing pre- and post-PROSTVAC peripheral antigen-specific T-cell responses, patients with PSA-specific immune responses had 100% 8-year BCR-FS, compared with 70.0% in nonresponders (p = 0.247). Those with any tumor-associated antigen response demonstrated 85.7% versus 66.7% 8-year BCR-FS (p = 0.149). Patients with CD4+ or CD8 + T-cell responses at the tumor site or invasive margin had 86.2% versus 58.9% 8-year BCR-FS (p = 0.257). CONCLUSION: Neoadjuvant PROSTVAC may have oncologic activity in localized prostate cancer, as we observed a longer BCR-FS in immune responders and no metastatic progression in a small cohort. Further investigation of the biological mechanism by which therapeutic immunotherapy may establish durable antitumor immunity in localized prostate cancer is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
molihuakai的应助被刘欣宇采纳,获得10
刚刚
刚刚
刚刚
科研通AI65的应助被萧小五采纳,获得10
刚刚
烟花的应助被科研助理795采纳,获得10
1秒前
丘比特的应助被不想上班采纳,获得10
1秒前
1秒前
xingyueli完成签到,获得积分10
1秒前
TGM_Hedwig完成签到,获得积分10
2秒前
2秒前
脑洞疼的应助被DADA采纳,获得10
2秒前
kinji完成签到,获得积分10
2秒前
蒋博芳发布了新的文献求助10
2秒前
Smile发布了新的文献求助20
4秒前
Luka完成签到,获得积分10
4秒前
Owen的应助被WN采纳,获得10
5秒前
xingyueli发布了新的文献求助10
5秒前
所所的应助被积极的黑猫采纳,获得10
5秒前
啊啊啊啊发布了新的文献求助10
5秒前
任性小凡完成签到,获得积分10
5秒前
6秒前
7秒前
gq100520发布了新的文献求助10
8秒前
永无完成签到,获得积分10
8秒前
墨白发布了新的文献求助10
9秒前
9秒前
9秒前
陶醉若云完成签到,获得积分10
10秒前
11秒前
YAN0221完成签到,获得积分10
11秒前
我是谁的应助被枫丶采纳,获得20
11秒前
11秒前
12秒前
momi发布了新的文献求助10
12秒前
火星上奇迹完成签到,获得积分20
12秒前
在水一方的应助被耶耶业采纳,获得10
14秒前
14秒前
YAN0221发布了新的文献求助10
15秒前
15秒前
麻辣王子发布了新的文献求助20
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193425
求助须知:如何正确求助?哪些是违规求助? 9579620
关于积分的说明 21866505
捐赠科研通 7793025
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484128